======= TMEM189-UBE2V1 =======
== Gene Information ==
* **Official Symbol**: N/A
* **Official Name**: N/A
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: N/A
* **UniProt**: N/A
* **Interactions**: [[https://thebiogrid.org/search.php?search=TMEM189-UBE2V1&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20TMEM189-UBE2V1|Open PubMed]]
* **OMIM**: N/A
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Has no ubiquitin ligase activity on its own. The UBE2V1- UBE2N heterodimer catalyzes the synthesis of non-canonical poly- ubiquitin chains that are linked through Lys-63. This type of poly-ubiquitination activates IKK and does not seem to involve protein degradation by the proteasome. Plays a role in the activation of NF-kappa-B mediated by IL1B, TNF, TRAF6 and TRAF2. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. Promotes TRIM5 capsid-specific restriction activity and the UBE2V1-UBE2N heterodimer acts in concert with TRIM5 to generate 'Lys-63'-linked polyubiquitin chains which activate the MAP3K7/TAK1 complex which in turn results in the induction and expression of NF-kappa-B and MAPK-responsive inflammatory genes. {ECO:0000269|PubMed:11057907, ECO:0000269|PubMed:20061386, ECO:0000269|PubMed:21512573, ECO:0000269|PubMed:9305758, ECO:0000269|PubMed:9418904, ECO:0000269|PubMed:9580084, ECO:0000269|PubMed:9705497}.
|Kua-UEV1 localn|
|UQ con|
|protein K63-linked ubiquitination|
|ubiquitin conjugating enzyme activity|
|postreplication repair|
|protein polyubiquitination|
|DNA repair|
|protein ubiquitination|
|DNA metabolic process|
|protein modification by small protein conjugation|
|cellular response to DNA damage stimulus|
|protein modification by small protein conjugation or removal|
|cellular response to stress|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp84|UM0125461 0.74μM R02 exp84]]|-2.65|
|[[:results:exp507|Monensin 0.3μM R08 exp507]]|-2.45|
|[[:results:exp457|Bisphenol F 50μM R08 exp457]]|-2.19|
|[[:results:exp89|Vemurafenib 6.6μM R02 exp89]]|-2.12|
|[[:results:exp516|Pyrazinamide 100μM R08 exp516]]|-2.07|
|[[:results:exp164|Q15 1 to 2μM on day4 R04 exp164]]|-2.04|
|[[:results:exp77|Prochlorperazine 5.2μM R02 exp77]]|-1.96|
|[[:results:exp7|Bortezomib 0.05μM R00 exp7]]|-1.93|
|[[:results:exp484|GSK-J5 1.5μM R08 exp484]]|-1.87|
|[[:results:exp79|Q15 2.7μM R02 exp79]]|-1.8|
|[[:results:exp215|Colchicine 0.009μM R05 exp215]]|2.75|
No correlation found to any other genes in chemogenomics.
Global Fraction of Cell Lines Where Essential: N/A
^Tissue^Fraction Of Cell Lines Where Essential^
== Essentiality in NALM6 ==
* **Essentiality Rank**: 5004
* **Expression level (log2 read counts)**: 2.74
{{:chemogenomics:nalm6 dist.png?nolink |}}